GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Effects of homologous ghrelins on the growth hormone/insulin-like growth factor-I axis in the tilapia, Oreochromis mossambicus.
Fox. Bradley K BK; Riley. Larry G LG; Dorough. Casey C; Kaiya. Hiroyuki H; Hirano. Tetsuya T; Grau. E Gordon EG
Key Findings
- Ghrelin‑C8 (100 nM) directly stimulates GH release from pituitary cells without affecting prolactin.
- Both ghrelin‑C8 and ‑C10 (100 nM) increase GH release in a way that is blocked by the GHS‑receptor antagonist [D‑Lys(3)]‑GHRP‑6.
- Intraperitoneal injection of low doses (0.1–1 ng/g) of ghrelin in tilapia raises plasma GH within 5 h and later boosts hepatic IGF‑I and GH‑receptor mRNA, with measurable plasma IGF‑I rise at 10 h.
Practical Outcomes
- For biohackers, this study reinforces that ghrelin‑based peptides act through the GHS‑receptor to increase GH and downstream IGF‑I, supporting their use for growth‑hormone boosting protocols. It also shows that very low doses can be effective in a vertebrate model, suggesting that micro‑gram per kilogram dosing in humans may be sufficient, but species differences mean human trials are still needed.
Summary
In Mozambique tilapia, two natural forms of ghrelin (C8 and C10) boost growth hormone (GH) release by binding to the GHS‑receptor, and later raise IGF‑I levels in the liver. The effect can be blocked by the GHS‑receptor antagonist GHRP‑6, confirming the pathway. Although the work is in fish, it mirrors what’s known in mammals and supports the idea that ghrelin‑type peptides can be used to stimulate the GH/IGF‑I axis.
Abstract
Ghrelin is a gut-brain peptide synthesized mainly in the oxyntic mucosal cells of the stomach, and has potent growth hormone (GH)-releasing and orexigenic activities. Recently, two forms of ghrelin, ghrelin-C8 and -C10, were identified in the Mozambique tilapia (Oreochromis mossambicus). The present study describes in vitro and in vivo effects of these endogenous ghrelins on the GH/insulin-like growth factor-I (IGF-I) axis. Ghrelin-C8 (100 nM) stimulated GH release from primary cultures of pituitary cells after 4 and 8 h of incubation, whereas no effect was seen on prolactin (PRL) release. Stimulatory effects of ghrelin-C8 and -C10 (100 nM) on GH release during 6 h of incubation were blocked by pre-incubation with GHS receptor antagonist, [D-Lys(3)]-GHRP-6 (10 microM). Intraperitoneal injection of ghrelin-C8 (1 ng/g body weight) and -C10 (0.1 and 1 ng/g body weight) significantly increased plasma GH levels after 5 h. Significant increases were observed also in hepatic expression of IGF-I and GH receptor (GHR) mRNA following injections of both forms of ghrelin (0.1 and 1 ng/g body weight), although there was no effect on plasma levels of IGF-I. In the next experiment, both forms of ghrelin (1 ng/g body weight) significantly increased plasma IGF-I levels 10 h after the injection. No significant effect of either ghrelin was observed on plasma PRL levels. Both forms of GHS receptor (GHSR-1a and -1b) were found in the pituitary, clearly indicating that tilapia ghrelins stimulate primarily GH release through the GHS receptor. Stimulation of hepatic expression of IGF-I and GHR suggests metabolic roles of ghrelin in tilapia.
Study Information
pubmed
2007
2007-04-01T00:00:00.000Z
10.2108/zsj.24.391
35
71